Physician

Eman Hamad, M.D.

According to 2025 Medicare claims, Eman Hamad, M.D. (NPI: 1366500415) practices advanced heart failure and transplant cardiology in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Philadelphia, PA. This provider's primary affiliated billing organization is TEMPLE FACULTY PRACTICE PLAN INC (NPI: 1457833485; TIN: 831002191) and primary practice location at 19140-5103.

Hamad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 131 traditional Medicare patients, billed 381 HCPCS/CPT codes, and received $42,800 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 2,451 prescription claims across 248 beneficiaries totaling $568,205 in drug costs, led by Entresto (Sacubitril/Valsartan). DME data shows 191 claims. Open Payments data shows 21 records totaling $43,030. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $49,450 and ending at $42,800. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $38,087 to $568,205. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $11,878 and ending at $6,729.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	185	667	$49,450
2016	205	597	$46,897
2017	272	854	$93,203
2018	293	732	$75,520
2019	215	537	$51,577
2020	194	545	$61,864
2021	197	597	$68,299
2022	186	637	$85,939
2023	142	394	$51,370
2024	131	381	$42,800

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	148	1,621	$38,087
2016	177	2,275	$75,777
2017	203	2,397	$63,249
2018	297	3,266	$134,744
2019	284	2,909	$135,518
2020	250	2,686	$145,991
2021	236	2,407	$184,777
2022	224	2,485	$320,117
2023	210	2,114	$437,903
2024	248	2,451	$568,205

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	22	$6,740
2016	N/R	41	$50,918
2017	N/R	43	$5,129
2018	N/R	201	$13,420
2019	N/R	291	$18,067
2020	41	437	$26,939
2021	N/R	112	$9,397
2022	N/R	214	$34,079
2023	N/R	200	$17,074
2024	N/R	191	$9,596

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	32	118	$172
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	83	112	$127
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	62	73	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Entresto	Sacubitril/Valsartan	225	9,420	$202,156
Farxiga	Dapagliflozin Propanediol	205	10,253	$187,625
Jardiance	Empagliflozin	30	1,560	$29,302
Eliquis	Apixaban	25	1,410	$26,307
Sildenafil Citrate	Sildenafil Citrate	16	480	$12,508

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	31	$3,861
J2260	Injection, milrinone lactate, 5 mg	N	N/R	31	$2,338
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	23	$1,655
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	31	$595
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$320

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$164	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	14	$42,866	Impulse Dynamics (USA) Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eman Hamad, M.D.?

Tedicare shows public-source Medicare data for Eman Hamad, M.D. (NPI 1366500415), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eman Hamad, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Eman Hamad, M.D.?

Eman Hamad, M.D. is linked to TEMPLE FACULTY PRACTICE PLAN INC (billing NPI 1457833485) in the available physician profile data.

Does Eman Hamad, M.D. have Open Payments data?

Eman Hamad, M.D. has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.